CAS: 63071-09-0; 2-Hydroxymethyl-3-Methylpyridine

相似化合物

4021-07-2 55589-47-4 59718-84-2

上下游产品

CAS号52814-41-2 2-乙酰氧基甲基-3-甲基吡啶... | CAS号22710-07-2 2,3-二甲基吡啶氮氧化物 | CAS号407-25-0 三氟乙酸酐(TFAH) | CAS号4370-22-3 2-(氯甲基)-3-甲基吡啶盐酸盐 | CAS号55589-47-4 3-甲基-2-吡啶醛 | CAS号4377-43-9 2-(氯甲基)-3-甲基吡啶

2,3-二甲基吡啶置于2,2,2-三氟苯乙酮,双氧水,Potassium Carbonate,乙腈,三氟乙酸酐体系中,用 二氯甲烷,水,叔丁醇 作为反应溶剂,化学反应 64.0H,反应生成 (3-甲基吡啶-2-基)甲醇
参考文献:Methyl Scanning And Revised Binding Mode Of 2-Pralidoxime,An Antidote For Nerve Agent Poisoning
标题:Methyl Scanning And Revised Binding Mode Of 2-Pralidoxime,An Antidote For Nerve Agent Poisoning
摘要:Organophosphorus Nerve Agents (Opnas) Inhibit Acetylcholinesterase (Ache) And,Despite The Chemical Weapons Convention Arms Control Treaty,Continue To Represent A Threat To Both Military Personnel And Civilians. 2-Pralidoxime (2-Pam) Is Currently The Only Therapeutic Countermeasure Approved By The United States Food And Drug Administration For Treating Opna Poisoning. However,2-Pam Is Not Centrally Active Due To Its Hydrophilicity And Resulting Poor Blood-Brain Barrier Permeability; Hence,These Deficiencies Warrant The Development Of More Hydrophobic Analogs. Specifically,Gaps Exist In Previously Published Structure Activity Relationship (Sar) Studies For 2-Pam,Thereby Making It Difficult To Rationally Design Novel Analogs That Are Concomitantly More Permeable And More Efficacious. In This Study,We Methodically Performed A Methyl Scan On The Core Pyridinium Of 2-Pam To Identify Ring Positions That Could Tolerate Both Additional Steric Bulk And Hydrophobicity. Subsequently,Sar-Guided Molecular Docking Was Used To Rationalize Hydropathically Feasible Binding Modes For 2-Pam And The Reported Derivatives. Overall,The Data Presented Herein Provide New Insights That May Facilitate The Rational Design Of More Efficacious 2-Pam Analogs.
DOI:10.1021/acsmedchemlett.9B00586

专利信息

专利号:US-4546198-A
优先权日:1983-01-18
标 题 :Asymmetric synthesis of esters and acids
发明人：STOUTAMIRE DONALD W
权利人:SHELL OIL CO
摘要:Stereoisomerically-enriched esters are prepared by treating a non-symmetrical ketene with a racemic or chiral tertiary-base-substituted alkylcarbinol. Optional hydrolysis of the esters gives the corresponding optically-active carboxylic acids corresponding to the non-symmetrical ketene.